ABBV-184: A Novel Survivin-specific TCR/CD3 Bispecific T-cell Engager is Active against Both Solid Tumor and Hematologic Malignancies.
Chervin AS, Stone JD, Konieczna I, Calabrese KM, Wang N, Haribhai D, Dong F, White MK, Rodriguez LE, Bukofzer GT, Ellis PA, Cosgrove C, Hecquet C, Clarin JD, Palma JP, Reilly EB.
Chervin AS, et al.
Mol Cancer Ther. 2023 Aug 1;22(8):903-912. doi: 10.1158/1535-7163.MCT-22-0770.
Mol Cancer Ther. 2023.
PMID: 37294945